<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pharmabioserv.com="http://pharmabioserv.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024">
  <link:schemaRef xlink:href="./phmb-20200430_taxonomy.zip/phmb-20200430_taxonomy/phmb-20200430.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:PuertoRicoConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:UnitedStatesConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:EuropeConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pharmabioserv.com:OtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupEMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:GlobalGroupTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-01</xbrli:startDate>
      <xbrli:endDate>2019-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2020-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerTotalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001304161</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pharmabioserv.com:MajorCustomerDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f" decimals="0" contextRef="c" unitRef="usd">956289.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:TreasuryStockValue id="f1" decimals="0" contextRef="c1" unitRef="usd">394278.0</us-gaap:TreasuryStockValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f2" decimals="0" contextRef="c2" unitRef="usd">2320.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f3" decimals="0" contextRef="c1" unitRef="usd">1423139.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f4" decimals="0" contextRef="c3" unitRef="usd">21564.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f5" decimals="0" contextRef="c4" unitRef="usd">62390.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <dei:CurrentFiscalYearEndDate id="f6" contextRef="c5">--10-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f7" decimals="0" contextRef="c1" unitRef="usd">20687529.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f8" decimals="0" contextRef="c6" unitRef="usd">-57925.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f9" decimals="0" contextRef="c7" unitRef="usd">21564.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:ConcentrationRiskPercentage1 id="f10" decimals="INF" contextRef="c8" unitRef="pure">0.122</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquityBeforeTreasuryStock id="f11" decimals="0" contextRef="c1" unitRef="usd">21195939.0</us-gaap:StockholdersEquityBeforeTreasuryStock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f12" decimals="0" contextRef="c9" unitRef="usd">396032.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f13" decimals="0" contextRef="c10" unitRef="usd">0.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f14" decimals="0" contextRef="c11" unitRef="usd">65755.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f15" decimals="0" contextRef="c4" unitRef="usd">87319.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f16" decimals="0" contextRef="c1" unitRef="usd">156496.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:IncomeTaxExpenseBenefit id="f17" decimals="0" contextRef="c10" unitRef="usd">81407.0</us-gaap:IncomeTaxExpenseBenefit>
  <dei:DocumentType id="f18" contextRef="c5">10-Q</dei:DocumentType>
  <us-gaap:ConcentrationRiskPercentage1 id="f19" decimals="INF" contextRef="c12" unitRef="pure">0.076</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f20" decimals="0" contextRef="c5" unitRef="usd">1699.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f21" decimals="0" contextRef="c13" unitRef="usd">65755.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:TreasuryStockValue id="f22" decimals="0" contextRef="c14" unitRef="usd">392579.0</us-gaap:TreasuryStockValue>
  <us-gaap:IncomeTaxExpenseBenefit id="f23" decimals="0" contextRef="c4" unitRef="usd">118213.0</us-gaap:IncomeTaxExpenseBenefit>
  <dei:DocumentPeriodEndDate id="f24" contextRef="c5">2020-04-30</dei:DocumentPeriodEndDate>
  <us-gaap:ConcentrationRiskPercentage1 id="f25" decimals="INF" contextRef="c15" unitRef="pure">0.266</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockSharesOutstanding id="f26" decimals="INF" contextRef="c1" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="f27" decimals="0" contextRef="c14" unitRef="usd">1590172.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="f28" decimals="0" contextRef="c3" unitRef="usd">21564.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:CapitalLeaseObligationsCurrent id="f29" decimals="0" contextRef="c1" unitRef="usd">11331.0</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:IncomeTaxExpenseBenefit id="f30" decimals="0" contextRef="c5" unitRef="usd">136702.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f31" decimals="0" contextRef="c16" unitRef="usd">1699.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f32" decimals="0" contextRef="c1" unitRef="usd">102133.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f33" decimals="0" contextRef="c10" unitRef="usd">327245.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <dei:AmendmentFlag id="f34" contextRef="c5">false</dei:AmendmentFlag>
  <us-gaap:ConcentrationRiskPercentage1 id="f35" decimals="INF" contextRef="c17" unitRef="pure">0.249</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquityBeforeTreasuryStock id="f36" decimals="0" contextRef="c14" unitRef="usd">21000085.0</us-gaap:StockholdersEquityBeforeTreasuryStock>
  <us-gaap:LoansPayableCurrent id="f37" decimals="0" contextRef="c1" unitRef="usd">643900.0</us-gaap:LoansPayableCurrent>
  <us-gaap:IncomeTaxExpenseBenefit id="f38" decimals="0" contextRef="c3" unitRef="usd">75258.0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:StockRepurchasedDuringPeriodValue id="f39" decimals="0" contextRef="c18" unitRef="usd">1699.0</us-gaap:StockRepurchasedDuringPeriodValue>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f40" decimals="0" contextRef="c10" unitRef="usd">-29461.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:NetIncomeLoss id="f41" decimals="0" contextRef="c10" unitRef="usd">687561.0</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingLeaseLiabilityCurrent id="f42" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f43" decimals="0" contextRef="c4" unitRef="usd">-596809.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <dei:EntityEmergingGrowthCompany id="f44" contextRef="c5">false</dei:EntityEmergingGrowthCompany>
  <us-gaap:ConcentrationRiskPercentage1 id="f45" decimals="INF" contextRef="c19" unitRef="pure">0.119</us-gaap:ConcentrationRiskPercentage1>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f46" decimals="INF" contextRef="c10" unitRef="shares">0.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:NetIncomeLoss id="f47" decimals="0" contextRef="c4" unitRef="usd">1178503.0</us-gaap:NetIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f48" decimals="0" contextRef="c5" unitRef="usd">91823.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f49" decimals="0" contextRef="c10" unitRef="usd">-1556707.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <dei:EntityCurrentReportingStatus id="f50" contextRef="c5">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:NetIncomeLoss id="f51" decimals="0" contextRef="c5" unitRef="usd">1214461.0</us-gaap:NetIncomeLoss>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f52" decimals="INF" contextRef="c18" unitRef="shares">2300.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:ConcentrationRiskPercentage1 id="f53" decimals="INF" contextRef="c20" unitRef="pure">0.146</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="f54" decimals="0" contextRef="c14" unitRef="usd">143600.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="f55" decimals="0" contextRef="c3" unitRef="usd">-365415.0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:LoansPayableCurrent id="f56" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:LoansPayableCurrent>
  <us-gaap:NetIncomeLoss id="f57" decimals="0" contextRef="c21" unitRef="usd">687561.0</us-gaap:NetIncomeLoss>
  <dei:EntityFilerCategory id="f58" contextRef="c5">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:StockholdersEquity id="f59" decimals="0" contextRef="c22" unitRef="usd">21357422.0</us-gaap:StockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="f60" decimals="0" contextRef="c1" unitRef="usd">1403936.0</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:ConcentrationRiskPercentage1 id="f61" decimals="INF" contextRef="c23" unitRef="pure">0.118</us-gaap:ConcentrationRiskPercentage1>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f62" decimals="INF" contextRef="c11" unitRef="shares">65772.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:InterestPaidNet id="f63" decimals="0" contextRef="c10" unitRef="usd">988.0</us-gaap:InterestPaidNet>
  <us-gaap:NetIncomeLoss id="f64" decimals="0" contextRef="c3" unitRef="usd">707483.0</us-gaap:NetIncomeLoss>
  <dei:EntitySmallBusiness id="f65" contextRef="c5">true</dei:EntitySmallBusiness>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f66" decimals="0" contextRef="c4" unitRef="usd">-11140.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:Liabilities id="f67" decimals="0" contextRef="c1" unitRef="usd">6834262.0</us-gaap:Liabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f68" decimals="0" contextRef="c14" unitRef="usd">19473069.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:NetIncomeLoss id="f69" decimals="0" contextRef="c24" unitRef="usd">471020.0</us-gaap:NetIncomeLoss>
  <us-gaap:ConcentrationRiskPercentage1 id="f70" decimals="INF" contextRef="c25" unitRef="pure">0.076</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CapitalLeaseObligationsCurrent id="f71" decimals="0" contextRef="c14" unitRef="usd">11030.0</us-gaap:CapitalLeaseObligationsCurrent>
  <pharmabioserv.com:StockRepurchaseDuringPeriodShares id="f72" decimals="INF" contextRef="c3" unitRef="shares">20050.0</pharmabioserv.com:StockRepurchaseDuringPeriodShares>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f73" decimals="0" contextRef="c5" unitRef="usd">-38880.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <dei:EntityInteractiveDataCurrent id="f74" contextRef="c5">Yes</dei:EntityInteractiveDataCurrent>
  <us-gaap:NetIncomeLoss id="f75" decimals="0" contextRef="c11" unitRef="usd">471020.0</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockValue id="f76" decimals="0" contextRef="c1" unitRef="usd">2341.0</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="f77" decimals="0" contextRef="c14" unitRef="usd">1381076.0</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:NetIncomeLoss id="f78" decimals="0" contextRef="c26" unitRef="usd">707483.0</us-gaap:NetIncomeLoss>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="f79" decimals="0" contextRef="c3" unitRef="usd">-25218.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ConcentrationRiskPercentage1 id="f80" decimals="INF" contextRef="c27" unitRef="pure">0.708</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherLiabilities id="f81" decimals="0" contextRef="c1" unitRef="usd">17950.0</us-gaap:OtherLiabilities>
  <us-gaap:NetIncomeLoss id="f82" decimals="0" contextRef="c28" unitRef="usd">526900.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f83" decimals="0" contextRef="c4" unitRef="usd">-1040629.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncomeTaxesPaid id="f84" decimals="0" contextRef="c10" unitRef="usd">211763.0</us-gaap:IncomeTaxesPaid>
  <dei:EntityShellCompany id="f85" contextRef="c5">false</dei:EntityShellCompany>
  <us-gaap:NetIncomeLoss id="f86" decimals="0" contextRef="c18" unitRef="usd">526900.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f87" decimals="0" contextRef="c5" unitRef="usd">-41688.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:InterestPaidNet id="f88" decimals="0" contextRef="c4" unitRef="usd">1904.0</us-gaap:InterestPaidNet>
  <us-gaap:ConcentrationRiskPercentage1 id="f89" decimals="INF" contextRef="c29" unitRef="pure">0.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockValue id="f90" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <us-gaap:Liabilities id="f91" decimals="0" contextRef="c14" unitRef="usd">6025569.0</us-gaap:Liabilities>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f92" decimals="INF" contextRef="c10" unitRef="usd1">0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:InterestPaidNet id="f93" decimals="0" contextRef="c5" unitRef="usd">2004.0</us-gaap:InterestPaidNet>
  <dei:DocumentFiscalPeriodFocus id="f94" contextRef="c5">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f95" decimals="0" contextRef="c1" unitRef="usd">696916.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:CommonStockValue id="f96" decimals="0" contextRef="c14" unitRef="usd">2340.0</us-gaap:CommonStockValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f97" decimals="0" contextRef="c3" unitRef="usd">-822917.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <dei:DocumentFiscalYearFocus id="f98" contextRef="c5">2020</dei:DocumentFiscalYearFocus>
  <us-gaap:ConcentrationRiskPercentage1 id="f99" decimals="INF" contextRef="c30" unitRef="pure">0.142</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f100" decimals="INF" contextRef="c10" unitRef="shares">23001627.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:InterestPaidNet id="f101" decimals="0" contextRef="c3" unitRef="usd">1425.0</us-gaap:InterestPaidNet>
  <dei:EntityCentralIndexKey id="f102" contextRef="c5">0001304161</dei:EntityCentralIndexKey>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f103" decimals="INF" contextRef="c4" unitRef="usd1">0.051</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f104" decimals="0" contextRef="c10" unitRef="usd">-121349.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:ConcentrationRiskPercentage1 id="f105" decimals="INF" contextRef="c31" unitRef="pure">0.099</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f106" decimals="INF" contextRef="c5" unitRef="usd1">0.053</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f107" decimals="0" contextRef="c4" unitRef="usd">-840431.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:IncomeTaxesPaid id="f108" decimals="0" contextRef="c4" unitRef="usd">326898.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:OtherLiabilities id="f109" decimals="0" contextRef="c14" unitRef="usd">17950.0</us-gaap:OtherLiabilities>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="f110" decimals="0" contextRef="c1" unitRef="usd">61337.0</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:IncomeTaxesPaid id="f111" decimals="0" contextRef="c5" unitRef="usd">211763.0</us-gaap:IncomeTaxesPaid>
  <us-gaap:ConsolidationPolicyTextBlock id="f112" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying condensed consolidated financial&#13;statements include the accounts of the Company and all of its wholly owned subsidiaries. All intercompany transactions and balances&#13;have been eliminated in consolidation.&amp;#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:PreferredStockValue id="f113" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:PreferredStockValue>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="f114" decimals="INF" contextRef="c3" unitRef="usd1">0.031</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f115" decimals="0" contextRef="c5" unitRef="usd">609610.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:ConcentrationRiskPercentage1 id="f116" decimals="INF" contextRef="c32" unitRef="pure">0.122</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockSharesOutstanding id="f117" decimals="INF" contextRef="c1" unitRef="shares">23001627.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="f118" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f119" decimals="INF" contextRef="c10" unitRef="shares">23029203.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncomeTaxesPaid id="f120" decimals="0" contextRef="c3" unitRef="usd">326898.0</us-gaap:IncomeTaxesPaid>
  <dei:EntityIncorporationStateCountryCode id="f121" contextRef="c5">DE</dei:EntityIncorporationStateCountryCode>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f122" decimals="0" contextRef="c10" unitRef="usd">24995.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:CommonStockSharesIssued id="f123" decimals="INF" contextRef="c1" unitRef="shares">23405753.0</us-gaap:CommonStockSharesIssued>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f124" decimals="INF" contextRef="c4" unitRef="shares">23032107.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInOperatingLiabilities id="f125" decimals="0" contextRef="c3" unitRef="usd">-324887.0</us-gaap:IncreaseDecreaseInOperatingLiabilities>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f126" decimals="0" contextRef="c4" unitRef="usd">138419.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:ConcentrationRiskPercentage1 id="f127" decimals="INF" contextRef="c33" unitRef="pure">0.266</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:PreferredStockSharesOutstanding id="f128" decimals="INF" contextRef="c14" unitRef="shares">0.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f129" decimals="0" contextRef="c1" unitRef="usd">28635923.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f130" decimals="INF" contextRef="c5" unitRef="shares">23002745.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f131" decimals="0" contextRef="c5" unitRef="usd">24995.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:LoansPayable id="f132" decimals="0" contextRef="c1" unitRef="usd">1287800.0</us-gaap:LoansPayable>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f133" decimals="0" contextRef="c10" unitRef="usd">-111919.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <dei:EntityFileNumber id="f134" contextRef="c5">000-50956</dei:EntityFileNumber>
  <us-gaap:ConcentrationRiskPercentage1 id="f135" decimals="INF" contextRef="c34" unitRef="pure">0.629</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="f136" decimals="0" contextRef="c14" unitRef="usd">67079.0</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="f137" decimals="INF" contextRef="c3" unitRef="shares">23002903.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f138" decimals="0" contextRef="c10" unitRef="usd">-29733.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f139" decimals="0" contextRef="c5" unitRef="usd">725524.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:PropertyPlantAndEquipmentDisposals id="f140" decimals="0" contextRef="c3" unitRef="usd">138419.0</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:ConcentrationRiskPercentage1 id="f141" decimals="INF" contextRef="c35" unitRef="pure">0.213</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f142" decimals="INF" contextRef="c4" unitRef="shares">23105166.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f143" decimals="0" contextRef="c10" unitRef="usd">0.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:EarningsPerSharePolicyTextBlock id="f144" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share of common stock is&#13;calculated by dividing net earnings by the weighted average number of shares of common stock outstanding. Diluted earnings per&#13;share includes the dilution of common stock equivalents, which include principally shares that may be issued upon the exercise&#13;of warrants, stock option and restricted stock unit awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The diluted weighted average shares of common&#13;stock outstanding were calculated using the treasury stock method for the respective periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:TaxesPayableCurrent id="f145" decimals="0" contextRef="c1" unitRef="usd">2058512.0</us-gaap:TaxesPayableCurrent>
  <us-gaap:CommonStockSharesIssued id="f146" decimals="INF" contextRef="c14" unitRef="shares">23397707.0</us-gaap:CommonStockSharesIssued>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f147" decimals="0" contextRef="c3" unitRef="usd">-23593.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f148" decimals="INF" contextRef="c5" unitRef="shares">23025958.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="f149" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the consolidated statements&#13;of cash flows, cash equivalents include investments in a money market obligations trust that is registered under the U.S. Investment&#13;Company Act of 1940, as amended, and liquid investments with original maturities of three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="f150" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards have established a fair&#13;value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when&#13;measuring fair value. A financial instrument&amp;#8217;s categorization within the fair value hierarchy is based upon the lowest level&#13;of input that is significant to the fair value measurement. Accounting standards have established three levels of inputs that may&#13;be used to measure fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 10%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt;:&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 90%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quoted prices in active markets for identical&#13;        assets and liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Level&amp;#160;2:&lt;/i&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Observable inputs other than Level 1 prices&#13;        such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions&#13;        (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally&#13;        from or corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company's financial&#13;instruments (excluding obligations under finance leases), cash and cash equivalents, accounts receivable, accounts payable and&#13;accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature. Management&#13;believes, based on current rates, that the fair value of its obligations under finance leases approximates the carrying amount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:ConcentrationRiskPercentage1 id="f151" decimals="INF" contextRef="c36" unitRef="pure">0.121</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LoansPayable id="f152" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:LoansPayable>
  <us-gaap:Revenues id="f153" decimals="0" contextRef="c37" unitRef="usd">394991.0</us-gaap:Revenues>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f154" decimals="INF" contextRef="c1" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="f155" decimals="INF" contextRef="c3" unitRef="shares">23068923.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="f156" decimals="0" contextRef="c4" unitRef="usd">-80329.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="f157" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;operates in three reportable business segments: (i) Puerto Rico technical compliance consulting, (ii) United States technical compliance&#13;consulting, and (iii) Europe technical compliance consulting. Accordingly, the accompanying condensed consolidated financial statements&#13;are presented to show these three reportable segments.&lt;/font&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f158" decimals="INF" contextRef="c1" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:OtherAssetsNoncurrent id="f159" decimals="0" contextRef="c1" unitRef="usd">368631.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:TreasuryStockShares id="f160" decimals="INF" contextRef="c1" unitRef="shares">404126.0</us-gaap:TreasuryStockShares>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f161" decimals="0" contextRef="c10" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:PreferredStockSharesAuthorized id="f162" decimals="INF" contextRef="c1" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ConcentrationRiskPercentage1 id="f163" decimals="INF" contextRef="c38" unitRef="pure">0.146</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockSharesOutstanding id="f164" decimals="INF" contextRef="c14" unitRef="shares">22995881.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f165" decimals="0" contextRef="c10" unitRef="usd">2262929.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f166" decimals="0" contextRef="c10" unitRef="usd">0.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f167" decimals="0" contextRef="c4" unitRef="usd">-10950.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:UseOfEstimates id="f168" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of condensed consolidated financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities&#13;at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting&#13;periods. Actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f169" decimals="0" contextRef="c4" unitRef="usd">86000.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f170" decimals="INF" contextRef="c14" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:TaxesPayableCurrent id="f171" decimals="0" contextRef="c14" unitRef="usd">2270000.0</us-gaap:TaxesPayableCurrent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f172" decimals="0" contextRef="c5" unitRef="usd">-41467.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f173" decimals="0" contextRef="c5" unitRef="usd">1200788.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ConcentrationRiskPercentage1 id="f174" decimals="INF" contextRef="c39" unitRef="pure">0.106</us-gaap:ConcentrationRiskPercentage1>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f175" decimals="0" contextRef="c5" unitRef="usd">0.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:Revenues id="f176" decimals="0" contextRef="c10" unitRef="usd">5647767.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f177" decimals="0" contextRef="c1" unitRef="usd">21801661.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="f178" decimals="0" contextRef="c3" unitRef="usd">-23267.0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f179" decimals="0" contextRef="c3" unitRef="usd">1212558.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle id="f180" decimals="0" contextRef="c3" unitRef="usd">86000.0</pharmabioserv.com:ObligationsUnderCapitalLeaseIncurredForAcquisitionOfVehicle>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f181" decimals="0" contextRef="c14" unitRef="usd">26633075.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f182" decimals="INF" contextRef="c40" unitRef="pure">0.101</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f183" decimals="0" contextRef="c10" unitRef="usd">-29733.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:TreasuryStockShares id="f184" decimals="INF" contextRef="c14" unitRef="shares">401826.0</us-gaap:TreasuryStockShares>
  <us-gaap:IncomeTaxDisclosureTextBlock id="f185" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 22, 2017, Public Law 115-97,&#13;commonly known as the Tax Cuts and Jobs Act of 2017 (the &amp;#8220;Tax Reform&amp;#8221;), was enacted. The Tax Reform is applicable&#13;to the Company commencing with its fiscal year 2018. The Tax Reform imposed a mandatory one-time transition tax (the&#13;&amp;#8220;Transition Tax&amp;#8221;) over foreign subsidiaries undistributed earnings and profits (&amp;#8220;E&amp;#38;Ps&amp;#8221;) earned&#13;prior to a date set by the statute. Based on the Company&amp;#8217;s E&amp;#38;Ps, the Transition Tax is estimated to be&#13;approximately $2.7 million. The Company elected to pay the Transition Tax liability over an eight year period starting with&#13;the Company&amp;#8217;s fiscal year 2019. In the past, most of these E&amp;#38;Ps&amp;#8217; were not repatriated and, considered to be&#13;reinvested indefinitely in the foreign location. Therefore no US tax liability was incurred with respect to these&#13;E&amp;#38;Ps&amp;#8217;, unless the E&amp;#38;Ps were repatriated as a dividend. After December 31, 2017, the Tax Reform established&#13;a 100% tax exemption on the foreign-source portion of dividends which are received attributable to E&amp;#38;Ps, with certain&#13;limitations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2011, Pharma-Bio, Pharma-PR and Pharma-Serv&#13;obtained a Grant of Industrial Tax Exemption pursuant to the terms and conditions set forth in Act No. 73 of May 28, 2008 (&amp;#8220;the&#13;Grant&amp;#8221;) issued by the Puerto Rico Industrial Development Company (&amp;#8220;PRIDCO&amp;#8221;). The Grant was effective as of November&#13;1, 2009 and covers a fifteen-year period. The Grant provides relief on various Puerto Rico taxes, including income tax, with certain&#13;limitations, for most of the activities carried on within Puerto Rico, including  services to parties located&#13;outside of Puerto Rico. Industrial Development Income (&amp;#8220;IDI&amp;#8221;) covered under the Grant are subject to a fixed income&#13;tax rate of 4%. In addition, IDI earnings distributions accumulated since November 1, 2009 are totally exempt from Puerto Rico&#13;earnings distribution tax.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Puerto Rico operations not covered in the exempt&#13;activities of the Grant are subject to Puerto Rico income tax at a maximum tax rate of 37.5% as provided by the 1994 Puerto Rico&#13;Internal Revenue Code, as amended. The operations carried out in the United States by the Company&amp;#8217;s subsidiaries, is taxed&#13;in the United States at a maximum regular federal income tax rate of 21%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred income tax assets and liabilities are&#13;computed for differences between the consolidated financial statements and tax bases of assets and liabilities that will result&#13;in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences&#13;are expected to affect taxable income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pharma-Spain, Pharma-IR and Pharma-Bio/Pharma-US&#13;have unused operating losses which result in a potential deferred tax asset. However, an allowance has been provided covering the&#13;total amount of such balance since it is uncertain whether the net operating losses can be used to offset future taxable income&#13;before their expiration dates. Realization of future tax benefits related to a deferred tax asset is dependent on many factors,&#13;including the company&amp;#8217;s ability to generate taxable income. Accordingly, the income tax benefit will be recognized when realization&#13;is determined to be more probable than not. These net operating losses are available to offset future taxable income through 2034&#13;for Pharma-Spain; indefinitely for Pharma-IR; until 2039 for Pharma-Bio/Pharma-US.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files income tax returns in the&#13;United States (federal and various states jurisdictions), Puerto Rico, Ireland, Spain and Brazil. The 2015 (2014 for Puerto Rico)&#13;through 2018 tax years are open and may be subject to potential examination in one or more jurisdictions. Currently, the Company&#13;has no federal, state, Puerto Rico or foreign income tax examination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="f186" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the Financial Accounting Standards&#13;Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers&#13;to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation&#13;of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize&#13;revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration&#13;to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of November&#13;1, 2018, by applying the modified-retrospective method to those contracts that were not completed as of that date. The results&#13;for reporting periods beginning after November 1, 2018, are presented in accordance with the new standard, although comparative&#13;information has not been restated and continues to be reported under the accounting standards and policies in effect for those&#13;periods. The adoption of this new standard had an immaterial impact on our reported total revenues and operating income as compared&#13;to what reported amounts would have been under the prior standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is primarily derived from: (1) time&#13;and materials contracts (representing approximately 99% of total revenues), which is recognized by applying the proportional performance&#13;model, whereby revenue is recognized as performance occurs, and (2) short-term fixed-fee contracts or &amp;#34;not to exceed&amp;#34; contracts&#13;(representing approximately 1% of total revenues), which revenue is recognized similarly, except that certain milestones also have&#13;to be reached before revenue is recognized. If the Company determines that a contract will result in a loss, the Company recognizes&#13;the estimated loss in the period in which such determination is made.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:PreferredStockSharesAuthorized id="f187" decimals="INF" contextRef="c14" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f188" decimals="0" contextRef="c4" unitRef="usd">-4475.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="f189" decimals="0" contextRef="c4" unitRef="usd">1473845.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f190" decimals="0" contextRef="c10" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f191" decimals="0" contextRef="c10" unitRef="usd">0.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:ConcentrationRiskPercentage1 id="f192" decimals="INF" contextRef="c41" unitRef="pure">0.687</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f193" decimals="0" contextRef="c42" unitRef="usd">20263663.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f194" decimals="0" contextRef="c43" unitRef="usd">4293041.0</us-gaap:Revenues>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f195" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f196" decimals="0" contextRef="c4" unitRef="usd">3.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:StockholdersEquity id="f197" decimals="0" contextRef="c44" unitRef="usd">21132403.0</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized id="f198" decimals="INF" contextRef="c1" unitRef="shares">50000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Revenues id="f199" decimals="0" contextRef="c45" unitRef="usd">5116682.0</us-gaap:Revenues>
  <us-gaap:ReceivablesPolicyTextBlock id="f200" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are recorded at their estimated&#13;realizable value. Accounts are deemed past due when payment has not been received within the stated time period. The Company's&#13;policy is to review individual past due amounts periodically and write off amounts for which all collection efforts are deemed&#13;to have been exhausted. Due to the nature of the Company&amp;#8217;s customers, bad debts are mainly accounted for using the direct&#13;write-off method whereby an expense is recognized only when a specific account is determined to be uncollectible. The effect of&#13;using this method approximates that of the allowance method.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:StockholdersEquity id="f201" decimals="0" contextRef="c14" unitRef="usd">20607506.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax id="f202" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentOfNoncreditPortionIncludedInNetIncomeAvailabeforsaleSecuritiesBeforeTax>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f203" decimals="0" contextRef="c4" unitRef="usd">4475.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f204" decimals="0" contextRef="c5" unitRef="usd">1.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:ConcentrationRiskPercentage1 id="f205" decimals="INF" contextRef="c46" unitRef="pure">0.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f206" decimals="INF" contextRef="c14" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f207" decimals="0" contextRef="c4" unitRef="usd">-15425.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f208" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock id="f209" decimals="0" contextRef="c3" unitRef="usd">2.0</pharmabioserv.com:ConversionOfCashlessExerciseOfOptionsToSharesOfCommonStock>
  <us-gaap:StockholdersEquity id="f210" decimals="0" contextRef="c47" unitRef="usd">2337.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f211" decimals="0" contextRef="c3" unitRef="usd">5150344.0</us-gaap:Revenues>
  <us-gaap:IncomeTaxPolicyTextBlock id="f212" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows an asset and liability approach&#13;method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory rates in effect&#13;at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the&#13;financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur.&#13;A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows guidance from the Financial&#13;Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) related to &lt;i&gt;Accounting for Uncertainty in Income Taxes,&lt;/i&gt; which includes a&#13;two-step approach to recognizing, de-recognizing and measuring uncertain tax positions. As of April 30, 2020, the Company had no&#13;significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f213" decimals="0" contextRef="c5" unitRef="usd">-41467.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:ConcentrationRiskPercentage1 id="f214" decimals="INF" contextRef="c48" unitRef="pure">0.073</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues id="f215" decimals="0" contextRef="c49" unitRef="usd">661356.0</us-gaap:Revenues>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments id="f216" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed id="f217" decimals="0" contextRef="c10" unitRef="usd">17913.0</pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed>
  <us-gaap:StockholdersEquity id="f218" decimals="0" contextRef="c50" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f219" decimals="0" contextRef="c51" unitRef="usd">-29733.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <dei:EntityCommonStockSharesOutstanding id="f220" decimals="INF" contextRef="c52" unitRef="shares">23001627.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:Revenues id="f221" decimals="0" contextRef="c53" unitRef="usd">133762.0</us-gaap:Revenues>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f222" decimals="0" contextRef="c4" unitRef="usd">24000.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:DepreciationDepletionAndAmortization id="f223" decimals="0" contextRef="c10" unitRef="usd">21579.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ConcentrationRiskPercentage1 id="f224" decimals="INF" contextRef="c54" unitRef="pure">0.105</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f225" decimals="0" contextRef="c55" unitRef="usd">1346956.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f226" decimals="0" contextRef="c56" unitRef="usd">141500.0</us-gaap:Revenues>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f227" decimals="0" contextRef="c3" unitRef="usd">-23267.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:DepreciationDepletionAndAmortization id="f228" decimals="0" contextRef="c4" unitRef="usd">48682.0</us-gaap:DepreciationDepletionAndAmortization>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f229" decimals="0" contextRef="c5" unitRef="usd">3649.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f230" decimals="0" contextRef="c57" unitRef="usd">7842.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="f231" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Owned property and equipment are stated at cost.&#13;Vehicles under finance leases are stated at the lower of fair market value or net present value of the minimum lease payments at&#13;the inception of the leases.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation of owned assets are provided for,&#13;when placed in service, in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service&#13;lives, using straight-line basis. Assets under finance leases are amortized over the lease term. While expenditures for repairs&#13;and maintenance are expensed when incurred. As of April 30, 2020 and October 31, 2019, the accumulated depreciation amounted to&#13;$481,325 and $509,275, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CommonStockSharesAuthorized id="f232" decimals="INF" contextRef="c14" unitRef="shares">50000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Revenues id="f233" decimals="0" contextRef="c58" unitRef="usd">2332.0</us-gaap:Revenues>
  <pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn id="f234" decimals="0" contextRef="c3" unitRef="usd">17411.0</pharmabioserv.com:IncomeTaxWithheldByClientsToBeUsedAsCreditInCompanysIncomeTaxReturn>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f235" decimals="0" contextRef="c11" unitRef="usd">7842.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:DepreciationDepletionAndAmortization id="f236" decimals="0" contextRef="c5" unitRef="usd">42611.0</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:StockholdersEquity id="f237" decimals="0" contextRef="c59" unitRef="usd">19111111.0</us-gaap:StockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f238" decimals="INF" contextRef="c60" unitRef="pure">0.116</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues id="f239" decimals="0" contextRef="c61" unitRef="usd">54447.0</us-gaap:Revenues>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="f240" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates for impairment its long-lived&#13;assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances indicate that&#13;the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the long-lived assets was&#13;present as of April 30, 2020 and October 31, 2019.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f241" decimals="0" contextRef="c62" unitRef="usd">-23267.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="f242" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;ORGANIZATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Pharma-Bio&#13;Serv, Inc. (&amp;#8220;Pharma-Bio&amp;#8221;) is a Delaware corporation organized on January 14, 2004. Pharma-Bio is the parent company&#13;of Pharma-Bio Serv PR, Inc. (&amp;#8220;Pharma-PR&amp;#8221;), Pharma Serv, Inc. (&amp;#8220;Pharma-Serv&amp;#8221;), and Scienza Labs, Inc. (&amp;#8220;Scienza&#13;Labs&amp;#8221;), each a&amp;#160;Puerto Rico corporation, Pharma-Bio Serv US, Inc. (&amp;#8220;Pharma-US&amp;#8221;), a Delaware corporation,&#13;Pharma-Bio Serv Validation &amp;#38; Compliance Limited (&amp;#8220;Pharma-IR&amp;#8221;), an Irish corporation currently inactive, Pharma-Bio&#13;Serv SL (&amp;#8220;Pharma-Spain&amp;#8221;), a Spanish limited liability company, and Pharma-Bio Serv Brasil Servicos de Consultoria Ltda.&#13;(&amp;#8220;Pharma-Brazil&amp;#8221;), a Brazilian limited liability company. Pharma-Bio, Pharma-PR, Pharma-Serv, Scienza Labs, Pharma-US,&#13;Pharma-IR, Pharma-Spain and Pharma-Brazil are collectively referred to as the &amp;#8220;Company.&amp;#8221; The Company operates in Puerto&#13;Rico, the United States, Ireland, Spain and Brazil under the name of Pharma-Bio Serv and is engaged in providing technical compliance&#13;consulting service.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The condensed consolidated balance sheet of&#13;the Company as of October 31, 2019 is derived from audited consolidated financial statements but does not include all disclosures&#13;required by generally accepted accounting principles. The unaudited interim condensed consolidated financial statements, include&#13;all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation&#13;of the financial position and results of operations and cash flows for the interim periods. The results of operations for the six&#13;months ended April 30, 2020 are not necessarily indicative of expected results for the full 2020 fiscal year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying financial data as of April&#13;30, 2020, and for the three-month and six-month periods ended April 30, 2020 and 2019 has been prepared by us, without audit, pursuant&#13;to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;). Certain information and footnote&#13;disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles have&#13;been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements&#13;and notes contained in our audited Consolidated Financial Statements and the notes thereto for the fiscal year ended October 31,&#13;2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying condensed consolidated financial&#13;statements include the accounts of the Company and all of its wholly owned subsidiaries. All intercompany transactions and balances&#13;have been eliminated in consolidation.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Segments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The Company&#13;operates in three reportable business segments: (i) Puerto Rico technical compliance consulting, (ii) United States technical compliance&#13;consulting, and (iii) Europe technical compliance consulting. Accordingly, the accompanying condensed consolidated financial statements&#13;are presented to show these three reportable segments.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of condensed consolidated financial&#13;statements in conformity with accounting principles generally accepted in the United States of America requires management to make&#13;estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities&#13;at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting&#13;periods. Actual results may differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards have established a fair&#13;value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when&#13;measuring fair value. A financial instrument&amp;#8217;s categorization within the fair value hierarchy is based upon the lowest level&#13;of input that is significant to the fair value measurement. Accounting standards have established three levels of inputs that may&#13;be used to measure fair value:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 10%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Level&amp;#160;1&lt;/i&gt;:&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 90%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Quoted prices in active markets for identical&#13;        assets and liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Level&amp;#160;2:&lt;/i&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Observable inputs other than Level 1 prices&#13;        such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions&#13;        (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally&#13;        from or corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;font style="font-size: 8pt"&gt;&lt;i&gt;Level&amp;#160;3&lt;/i&gt;:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying value of the Company's financial&#13;instruments (excluding obligations under finance leases), cash and cash equivalents, accounts receivable, accounts payable and&#13;accrued liabilities, are considered reasonable estimates of fair value due to their liquidity or short-term nature. Management&#13;believes, based on current rates, that the fair value of its obligations under finance leases approximates the carrying amount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the Financial Accounting Standards&#13;Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers&#13;to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation&#13;of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize&#13;revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration&#13;to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of November&#13;1, 2018, by applying the modified-retrospective method to those contracts that were not completed as of that date. The results&#13;for reporting periods beginning after November 1, 2018, are presented in accordance with the new standard, although comparative&#13;information has not been restated and continues to be reported under the accounting standards and policies in effect for those&#13;periods. The adoption of this new standard had an immaterial impact on our reported total revenues and operating income as compared&#13;to what reported amounts would have been under the prior standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is primarily derived from: (1) time&#13;and materials contracts (representing approximately 99% of total revenues), which is recognized by applying the proportional performance&#13;model, whereby revenue is recognized as performance occurs, and (2) short-term fixed-fee contracts or &amp;#34;not to exceed&amp;#34; contracts&#13;(representing approximately 1% of total revenues), which revenue is recognized similarly, except that certain milestones also have&#13;to be reached before revenue is recognized. If the Company determines that a contract will result in a loss, the Company recognizes&#13;the estimated loss in the period in which such determination is made.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For purposes of the consolidated statements&#13;of cash flows, cash equivalents include investments in a money market obligations trust that is registered under the U.S. Investment&#13;Company Act of 1940, as amended, and liquid investments with original maturities of three months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable are recorded at their estimated&#13;realizable value. Accounts are deemed past due when payment has not been received within the stated time period. The Company's&#13;policy is to review individual past due amounts periodically and write off amounts for which all collection efforts are deemed&#13;to have been exhausted. Due to the nature of the Company&amp;#8217;s customers, bad debts are mainly accounted for using the direct&#13;write-off method whereby an expense is recognized only when a specific account is determined to be uncollectible. The effect of&#13;using this method approximates that of the allowance method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows an asset and liability approach&#13;method of accounting for income taxes. This method measures deferred income taxes by applying enacted statutory rates in effect&#13;at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the&#13;financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur.&#13;A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company follows guidance from the Financial&#13;Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) related to &lt;i&gt;Accounting for Uncertainty in Income Taxes,&lt;/i&gt; which includes a&#13;two-step approach to recognizing, de-recognizing and measuring uncertain tax positions. As of April 30, 2020, the Company had no&#13;significant uncertain tax positions that would be reduced as a result of a lapse of the applicable statute of limitations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Owned property and equipment are stated at cost.&#13;Vehicles under finance leases are stated at the lower of fair market value or net present value of the minimum lease payments at&#13;the inception of the leases.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation of owned assets are provided for,&#13;when placed in service, in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service&#13;lives, using straight-line basis. Assets under finance leases are amortized over the lease term. While expenditures for repairs&#13;and maintenance are expensed when incurred. As of April 30, 2020 and October 31, 2019, the accumulated depreciation amounted to&#13;$481,325 and $509,275, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates for impairment its long-lived&#13;assets to be held and used, and long-lived assets to be disposed of, whenever events or changes in circumstances indicate that&#13;the carrying amount of an asset may not be recoverable. Based on management estimates, no impairment of the long-lived assets was&#13;present as of April 30, 2020 and October 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock-based compensation expense is recognized&#13;in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation cost is measured&#13;at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally&#13;represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates the fair value&#13;of stock options using the Black-Scholes option-pricing model at the grant date, while for restricted stock units the fair market&#13;value of the units is determined by Company&amp;#8217;s share market value at grant date. Excess tax benefits related to stock-based&#13;compensation are reflected as cash flows from financing activities rather than cash flows from operating activities. The Company&#13;has not recognized such cash flows from financing activities since there has been no tax benefit related to the stock-based compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Earnings Per Share of Common Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share of common stock is&#13;calculated by dividing net earnings by the weighted average number of shares of common stock outstanding. Diluted earnings per&#13;share includes the dilution of common stock equivalents, which include principally shares that may be issued upon the exercise&#13;of warrants, stock option and restricted stock unit awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The diluted weighted average shares of common&#13;stock outstanding were calculated using the treasury stock method for the respective periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Foreign Operations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company&amp;#8217;s&#13;foreign subsidiaries is its local currency. The assets and liabilities of the Company&amp;#8217;s foreign subsidiaries are translated&#13;into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average&#13;exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional currency other&#13;than the U.S. dollar is included as a cumulative translation adjustment in stockholders&amp;#8217; equity and as a component of comprehensive&#13;income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s intercompany accounts are&#13;typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of&#13;intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation&#13;adjustment in stockholders&amp;#8217; equity and as a component of comprehensive income, while gains and losses resulting from the&#13;remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in&#13;the foreseeable future are recorded in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events&#13;through&amp;#160;the filing date of this report. The Company has determined that there are no events occurring in this period that&#13;required disclosure or adjustment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain reclassifications have been made to&#13;the April 30, 2019 condensed consolidated financial statements to conform them to the April 30, 2020 condensed consolidated financial&#13;statements presentation. Such reclassifications do not affect net income as previously reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&#13;Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 is intended to increase transparency and comparability of accounting&#13;for lease transactions. For all leases with terms greater than twelve months, the new guidance will require lessees to recognize&#13;right-of-use assets and corresponding lease liabilities on the balance sheet and to disclose qualitative and quantitative information&#13;about lease transactions. The new standard maintains a distinction between finance leases and operating leases. As a result, the&#13;effect of leases in the statement of operations and statement of cash flows is largely unchanged. In July 2018, the FASB issued&#13;ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that&#13;applies the new lease requirements through a cumulative-effect adjustment in the period of adoption.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective November 1, 2019, the Company adopted&#13;the new lease accounting standard using the modified retrospective transition option of applying the new standard at the adoption&#13;date. We categorize leases at their inception as either operating or finance leases. The Company leases include an operational&#13;lease for office space and a finance lease agreement for a vehicle. The adoption of the new standard resulted in the operating&#13;lease being included in operating lease right-of-use assets, current operating lease liabilities, and long-term operating lease&#13;liabilities in our condensed consolidated balance sheets, but did not have an impact on the Company&amp;#8217;s beginning balance of&#13;retained earnings, consolidated statement of operations or statement of cash flows. Finance leases are included in net property&#13;and equipment, current installments of long-term debt, and long-term debt in our condensed consolidated balance sheets. The most&#13;significant impact was the recognition of right-of-use assets and lease liabilities on account of the Company&amp;#8217;s operating&#13;leases. The Company recognized $941,009 of right-of-use assets and $911,922 in operating lease liabilities at November 1, 2019.&#13;As of April 30, 2020, the total right-of-use assets related to the Company&amp;#8217;s operating leases was $874,840 and operating&#13;lease liabilities current and non-current were approximately $156,496 and $696,916, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Recent accounting pronouncements pending adoption&#13;not discussed above or in the 2019 Form 10-K are either not applicable or will not have or are not expected to have a material&#13;impact on us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="f243" decimals="0" contextRef="c63" unitRef="usd">107947.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f244" decimals="0" contextRef="c5" unitRef="usd">10260934.0</us-gaap:Revenues>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock id="f245" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated subsequent events&#13;through&amp;#160;the filing date of this report. The Company has determined that there are no events occurring in this period that&#13;required disclosure or adjustment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentNet id="f246" decimals="0" contextRef="c1" unitRef="usd">250752.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f247" decimals="0" contextRef="c64" unitRef="usd">-11734.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:DepreciationDepletionAndAmortization id="f248" decimals="0" contextRef="c3" unitRef="usd">21844.0</us-gaap:DepreciationDepletionAndAmortization>
  <pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed id="f249" decimals="0" contextRef="c4" unitRef="usd">86773.0</pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed>
  <us-gaap:ConcentrationRiskPercentage1 id="f250" decimals="INF" contextRef="c65" unitRef="pure">0.222</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues id="f251" decimals="0" contextRef="c4" unitRef="usd">9716541.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f252" decimals="0" contextRef="c66" unitRef="usd">-304688.0</us-gaap:StockholdersEquity>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="f253" decimals="0" contextRef="c18" unitRef="usd">-11734.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed id="f254" decimals="0" contextRef="c5" unitRef="usd">17913.0</pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed>
  <us-gaap:Revenues id="f255" decimals="0" contextRef="c67" unitRef="usd">9297592.0</us-gaap:Revenues>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="f256" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock-based compensation expense is recognized&#13;in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation cost is measured&#13;at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally&#13;represents the vesting period, and includes an estimate of awards that will be forfeited. The Company calculates the fair value&#13;of stock options using the Black-Scholes option-pricing model at the grant date, while for restricted stock units the fair market&#13;value of the units is determined by Company&amp;#8217;s share market value at grant date. Excess tax benefits related to stock-based&#13;compensation are reflected as cash flows from financing activities rather than cash flows from operating activities. The Company&#13;has not recognized such cash flows from financing activities since there has been no tax benefit related to the stock-based compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:GainLossOnDispositionOfAssets id="f257" decimals="0" contextRef="c10" unitRef="usd">4918.0</us-gaap:GainLossOnDispositionOfAssets>
  <pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed id="f258" decimals="0" contextRef="c3" unitRef="usd">86773.0</pharmabioserv.com:AccumulatedDepreciationOnPropertyAndEquipmentDisposed>
  <us-gaap:Assets id="f259" decimals="0" contextRef="c1" unitRef="usd">28635923.0</us-gaap:Assets>
  <us-gaap:ConcentrationRiskPercentage1 id="f260" decimals="INF" contextRef="c68" unitRef="pure">0.516</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f261" decimals="0" contextRef="c69" unitRef="usd">2340.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f262" decimals="0" contextRef="c70" unitRef="usd">784353.0</us-gaap:Revenues>
  <us-gaap:MarketableSecuritiesTextBlock id="f263" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;On September&#13;17, 2018 (the &amp;#8220;Sales Closing Date&amp;#8221;), the Company sold substantially all of its Lab business assets (the &amp;#8220;Laboratory&#13;Assets&amp;#8221;). Upon the completion of the Laboratory Assets sale, the Company received, as partial payment, a $3 million Promissory&#13;Note from the purchaser. The Promissory Note is composed of two tranches; (i) Tranche A for $2 million and secured with lab equipment&#13;and (ii) Tranche B for $1 million which is unsecured. The interest rate accrual is 3% for Tranche A and 5% for Tranche B. As of&#13;April 30, 2020, pursuant to the terms of the Promissory Note, the Company has collected $1,750,000. The Promissory Note final installment&#13;of $1,250,000 from Tranche A is due September 17, 2020.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f264" decimals="0" contextRef="c10" unitRef="usd">657828.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:GainLossOnDispositionOfAssets id="f265" decimals="0" contextRef="c5" unitRef="usd">4918.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="f266" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The functional currency of the Company&amp;#8217;s&#13;foreign subsidiaries is its local currency. The assets and liabilities of the Company&amp;#8217;s foreign subsidiaries are translated&#13;into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average&#13;exchange rates prevailing during the period. The cumulative translation effect for subsidiaries using a functional currency other&#13;than the U.S. dollar is included as a cumulative translation adjustment in stockholders&amp;#8217; equity and as a component of comprehensive&#13;income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s intercompany accounts are&#13;typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of&#13;intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation&#13;adjustment in stockholders&amp;#8217; equity and as a component of comprehensive income, while gains and losses resulting from the&#13;remeasurement of intercompany receivables from those international subsidiaries for which the Company anticipates settlement in&#13;the foreseeable future are recorded in the consolidated statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:Revenues id="f267" decimals="0" contextRef="c71" unitRef="usd">155950.0</us-gaap:Revenues>
  <us-gaap:StockholdersEquity id="f268" decimals="0" contextRef="c72" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:DebtDisclosureTextBlock id="f269" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;On&#13;April 23, 2020, Pharma-PR, Pharma-Serv, and Pharma-US (collectively, the &amp;#8220;&lt;/font&gt;Borrowers&lt;font style="background-color: white"&gt;&amp;#8221;)&#13;entered into loan agreements and related promissory notes (the &amp;#8220;&lt;/font&gt;SBA Loan Documents&lt;font style="background-color: white"&gt;&amp;#8221;)&#13;to receive U.S. Small Business Administration Loans (the &amp;#8220;&lt;/font&gt;SBA Loans&lt;font style="background-color: white"&gt;&amp;#8221;).&#13;These loans were originated pursuant to the Paycheck Protection Program (the &amp;#8220;&lt;/font&gt;PPP&lt;font style="background-color: white"&gt;&amp;#8221;)&#13;established under the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#8220;&lt;/font&gt;CARES Act&lt;font style="background-color: white"&gt;&amp;#8221;),&#13;and in the aggregate amount of $1,931,700 (the &amp;#8220;&lt;/font&gt;Loan Proceeds&lt;font style="background-color: white"&gt;&amp;#8221;). The&#13;Borrowers received the Loan Proceeds on April 23, 2020. In accordance with the SBA Loan Documents, the SBA Loans (i) have a&#13;fixed interest rate of 1%, (ii) begin repayment six months from the date of disbursement of each SBA Loan, and (iii)  &#13; mature two years from the date of first disbursement. These SBA Loans have  no prepayment penalty.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:Assets id="f270" decimals="0" contextRef="c14" unitRef="usd">26633075.0</us-gaap:Assets>
  <us-gaap:ConcentrationRiskPercentage1 id="f271" decimals="INF" contextRef="c73" unitRef="pure">0.213</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues id="f272" decimals="0" contextRef="c74" unitRef="usd">23039.0</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f273" decimals="0" contextRef="c5" unitRef="usd">1172994.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SegmentReportingDisclosureTextBlock id="f274" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s segments are based on the&#13;organizational structure for which financial results are regularly evaluated by the Company&amp;#8217;s chief operating decision maker&#13;to determine resource allocation and assess performance. Each reportable segment is managed by its own management team and reports&#13;to executive management. The Company has three reportable segments: (i) Puerto Rico technical compliance consulting, (ii) United&#13;States technical compliance consulting, and (iii) Europe technical compliance consulting. These reportable segments provide services&#13;primarily to the pharmaceutical, chemical, medical device and biotechnology industries in their respective markets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents information about&#13;the reported revenue from services and earnings from operations of the Company for the three-month and six-month periods ended&#13;in April 30, 2020 and 2019. There is no intersegment revenue for the mentioned periods. Corporate expenses that support the operating&#13;units have been allocated to the segments. Asset information by reportable segment is not presented, since the Company does not&#13;produce such information internally, nor does it use such data to manage its business.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Three months ended April 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;b&gt;Six months ended April 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;REVENUES:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; text-indent: 9pt"&gt;Puerto Rico consulting&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;5,116,682&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;4,293,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;9,297,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;8,181,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;United States consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;394,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;784,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,188,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Europe consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Other segments&amp;#185;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total consolidated revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,647,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,260,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,716,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;INCOME (LOSS) BEFORE TAXES:&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Puerto Rico consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;633,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;581,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,150,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;956,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;United States consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: right"&gt;(61,930&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Europe consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,684&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,925&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Other segments&amp;#185;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;195,506&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;324,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 0.25in"&gt;Total consolidated income before taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;768,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;782,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,351,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,296,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="border-top: black 1pt solid; width: 2%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#185;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1pt solid; width: 98%; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Other segments represent activities that fall below the reportable threshold and are carried out in Puerto Rico and Brazil. These activities include a Brazilian compliance consulting division and corporate headquarters, as applicable.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long lived assets (property and equipment) as&#13;of April 30, 2020 and October 31, 2019, and related depreciation and amortization expense for the three and six months ended April&#13;30, 2020 and 2019, were concentrated in the corporate headquarters in Puerto Rico. Accordingly, depreciation expense and acquisition&#13;of property and equipment, as presented in the statements of cash flows are mainly related to the corporate headquarters.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:GainLossOnDispositionOfAssets id="f275" decimals="0" contextRef="c3" unitRef="usd">47392.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f276" decimals="0" contextRef="c1" unitRef="usd">874840.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:StockholdersEquity id="f277" decimals="0" contextRef="c75" unitRef="usd">1381076.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f278" decimals="0" contextRef="c" unitRef="usd">8181595.0</us-gaap:Revenues>
  <us-gaap:EarningsPerShareTextBlock id="f279" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following data shows the amounts used in&#13;the calculations of basic and diluted earnings per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Three months&amp;#160;ended April 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Six months&amp;#160;ended April 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net income available to common equity holders - used to compute&amp;#160;basic and diluted earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$687,561&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$707,483&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$1,214,461&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$1,178,503&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares - used to compute basic earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,001,627&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,002,903&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,002,745&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,032,107&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effect of options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;27,576&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;66,020&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,213&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;73,059&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of shares - used to compute diluted earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,029,203&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,068,923&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,025,958&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,105,166&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the three-month and six-month periods ended&#13;April 30, 2020, options for the purchase of shares of 340,000 common stock were not considered in computing diluted earnings per&#13;share because the effect was antidilutive. In addition, warrants and options for the purchase of 1,000,000 and 80,000 shares of&#13;common stock, respectively, for the three-month and six-month periods ended April 30, 2019, were not included in computing diluted&#13;earnings per share because their effects were also antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription id="f280" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain reclassifications have been made to&#13;the April 30, 2019 condensed consolidated financial statements to conform them to the April 30, 2020 condensed consolidated financial&#13;statements presentation. Such reclassifications do not affect net income as previously reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ConcentrationRiskPercentage1 id="f281" decimals="INF" contextRef="c76" unitRef="pure">0.149</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:Revenues id="f282" decimals="0" contextRef="c2" unitRef="usd">1188001.0</us-gaap:Revenues>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="f283" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;On&#13;December 2014, the Company entered into a stock warrant agreement with a firm in exchange for providing (i) business&#13;development and (ii) mergers and acquisition services to the Company. The Company warrants for the purchase of 1,000,000&#13;common shares issued to this firm expired on December 1, 2019 without being exercised.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:StockholdersEquity id="f284" decimals="0" contextRef="c77" unitRef="usd">19473069.0</us-gaap:StockholdersEquity>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f285" decimals="0" contextRef="c3" unitRef="usd">684216.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:Revenues id="f286" decimals="0" contextRef="c6" unitRef="usd">233231.0</us-gaap:Revenues>
  <us-gaap:ConcentrationRiskDisclosureTextBlock id="f287" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s domestic cash and cash equivalents&#13;consist of cash deposits in FDIC insured banks (substantially covered by FDIC insurance by the spread of deposits in multiple FDIC&#13;insured banks), a money market obligations trust registered under the US Investment Company Act of 1940, as amended, and U.S. Treasury&#13;securities with maturities of three months or less. In the foreign markets we serve, we also maintain cash deposits in foreign&#13;banks, which have no specific insurance. No losses have been experienced or are expected on these accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Accounts receivable and revenues&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management deems all of its accounts receivable&#13;to be fully collectible, and, as such, does not maintain any allowances for uncollectible receivables.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company's revenues, and the related receivables,&#13;are concentrated in the pharmaceutical industry in Puerto Rico, the United States, Ireland, Spain and Brazil. Although a few customers&#13;represent a significant source of revenue, the Company&amp;#8217;s functions are not a continuous process, accordingly, the client&#13;base for which the services are typically rendered, on a project-by-project basis, changes regularly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provided a substantial portion of&#13;its services to five customers, which accounted for 10% or more of its revenues in either of the three-month and six-month periods&#13;ended April 30, 2020 and 2019. During the three months ended April 30, 2020, revenues from these customers were 24.9%, 9.3%, 14.6%,&#13;11.8% and 7.6%, or a total of 68.2%, as compared to the same period last year of 0.0%, 11.1%, 9.9%, 12.2% and 26.6%, or a total&#13;of 59.8%, respectively. During the six months ended April 30, 2020, revenues from these customers were 21.3%, 12.1%, 14.6%, 10.6%&#13;and 10.1%, or a total of 68.7%, as compared to the same period last year of 0.0%, 7.3%, 10.5%, 11.6% and 22.2%, or a total of 51.6%,&#13;respectively. At April 30, 2020, amounts due from these customers represented 85.2% of the Company&amp;#8217;s total accounts receivable&#13;balance. This customer information is based on revenues earned from said customers at the segment level because in management&amp;#8217;s&#13;opinion contracts by segments are totally independent of each other, and therefore such information is more meaningful to the reader.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the global level, five global groups of affiliated&#13;companies accounted for 10% or more of its revenues in either of the three-month and six-month periods ended April 30, 2020 and&#13;2019. During the three months ended April 30, 2020, aggregate revenues from these global groups of affiliated companies were 24.9%,&#13;11.9%, 14.6%, 11.8%, and 7.6%, or a total of 70.8%, as compared to the same period last year for 0.0%, 14.2%, 9.9%, 12.2%, and&#13;26.6%, or a total of 62.9%, respectively. During the six months ended April 30, 2020, aggregate revenues from these global group&#13;of affiliated companies were 21.3%, 14.9%, 14.6%, 10.6% and 10.1%, or a total of 71.5%, as compared to the same period last year&#13;for 0.0%, 10.7%, 10.5%, 11.6% and 22.2%, or a total of 55.0%, respectively. At April 30, 2020, amounts due from these global groups&#13;of affiliated companies represented 86.1% of total accounts receivable balance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;As&#13;of April 30, 2020, one of the Company&amp;#8217;s customers (representing 10.2% of revenues during the six months ended April 30,&#13;2020) owes the Company approximately $5.3 million (including $1.25 million from a Promissory Note due September 2020). This&#13;outstanding obligation represents approximately 21.6% of the Company&amp;#8217;s total working capital. The Company is providing&#13;multiple services to this customer related to their construction and validation of a manufacturing facility in Puerto Rico.&#13; A significant portion of the&#13;customer&amp;#8217;s funding comes from different financing sources. Management estimates that collectability of the account is&#13;reasonably assured, accordingly, no provision for losses, if any, have been recorded in the financial statements.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:GainLossOnDispositionOfAssets id="f288" decimals="0" contextRef="c4" unitRef="usd">47392.0</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:OtherAssetsNoncurrent id="f289" decimals="0" contextRef="c14" unitRef="usd">367437.0</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:ConcentrationRiskPercentage1 id="f290" decimals="INF" contextRef="c78" unitRef="pure">0.146</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f291" decimals="0" contextRef="c79" unitRef="usd">143600.0</us-gaap:StockholdersEquity>
  <us-gaap:Revenues id="f292" decimals="0" contextRef="c9" unitRef="usd">113714.0</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax id="f293" decimals="0" contextRef="c4" unitRef="usd">1163078.0</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f294" decimals="0" contextRef="c10" unitRef="usd">-15548.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:SharesIssued id="f295" decimals="INF" contextRef="c47" unitRef="shares">23373817.0</us-gaap:SharesIssued>
  <us-gaap:CostOfRevenue id="f296" decimals="0" contextRef="c10" unitRef="usd">3778867.0</us-gaap:CostOfRevenue>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f297" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued ASU 2016-02,&#13;Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 is intended to increase transparency and comparability of accounting&#13;for lease transactions. For all leases with terms greater than twelve months, the new guidance will require lessees to recognize&#13;right-of-use assets and corresponding lease liabilities on the balance sheet and to disclose qualitative and quantitative information&#13;about lease transactions. The new standard maintains a distinction between finance leases and operating leases. As a result, the&#13;effect of leases in the statement of operations and statement of cash flows is largely unchanged. In July 2018, the FASB issued&#13;ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that&#13;applies the new lease requirements through a cumulative-effect adjustment in the period of adoption.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective November 1, 2019, the Company adopted&#13;the new lease accounting standard using the modified retrospective transition option of applying the new standard at the adoption&#13;date. We categorize leases at their inception as either operating or finance leases. The Company leases include an operational&#13;lease for office space and a finance lease agreement for a vehicle. The adoption of the new standard resulted in the operating&#13;lease being included in operating lease right-of-use assets, current operating lease liabilities, and long-term operating lease&#13;liabilities in our condensed consolidated balance sheets, but did not have an impact on the Company&amp;#8217;s beginning balance of&#13;retained earnings, consolidated statement of operations or statement of cash flows. Finance leases are included in net property&#13;and equipment, current installments of long-term debt, and long-term debt in our condensed consolidated balance sheets. The most&#13;significant impact was the recognition of right-of-use assets and lease liabilities on account of the Company&amp;#8217;s operating&#13;leases. The Company recognized $941,009 of right-of-use assets and $911,922 in operating lease liabilities at November 1, 2019.&#13;As of April 30, 2020, the total right-of-use assets related to the Company&amp;#8217;s operating leases was $874,840 and operating&#13;lease liabilities current and non-current were approximately $156,496 and $696,916, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:StockholdersEquity id="f298" decimals="0" contextRef="c80" unitRef="usd">-392579.0</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeaseRightOfUseAsset id="f299" decimals="0" contextRef="c14" unitRef="usd">0.0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:ConcentrationRiskPercentage1 id="f300" decimals="INF" contextRef="c81" unitRef="pure">0.106</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f301" decimals="0" contextRef="c4" unitRef="usd">604669.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:GrossProfit id="f302" decimals="0" contextRef="c10" unitRef="usd">1868900.0</us-gaap:GrossProfit>
  <us-gaap:SharesIssued id="f303" decimals="INF" contextRef="c72" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f304" decimals="0" contextRef="c1" unitRef="usd">481325.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f305" decimals="0" contextRef="c82" unitRef="usd">2340.0</us-gaap:StockholdersEquity>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f306" decimals="0" contextRef="c5" unitRef="usd">-26874.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CostOfRevenue id="f307" decimals="0" contextRef="c4" unitRef="usd">6644079.0</us-gaap:CostOfRevenue>
  <us-gaap:SharesIssued id="f308" decimals="INF" contextRef="c69" unitRef="shares">23397707.0</us-gaap:SharesIssued>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f309" decimals="INF" contextRef="c10" unitRef="shares">27576.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f310" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 13, 2014, the Board of Directors of&#13;the Company authorized the Company to repurchase up to two million shares of its outstanding common stock (the &amp;#8220;Repurchase&#13;Program&amp;#8221;). The timing, manner, price and amount of any repurchases under the Repurchase Program will be at the discretion&#13;of the Company, subject to the requirements of the Securities Exchange Act of 1934, as amended, and related rules. The Repurchase&#13;Program does not oblige the Company to repurchase any shares and it may be modified, suspended or terminated at any time and for&#13;any reason. No shares will be repurchased under the Repurchase Program directly from directors or officers of the Company. As of&#13;April 30, 2020 and October 31, 2019, a total of 341,154 and 338,854 shares of the Company&amp;#8217;s common stock were purchased under&#13;the Repurchase Program for an aggregate amount of $331,306 and $329,607, respectively. During April 2020, the Company suspended purchases under the Repurchase Program to conserve cash due to the economic uncertainty&#13;caused by the coronavirus pandemic. Also, on November 26, 2018, the Company&#13;repurchased 62,972 shares of common stock, outside of the Repurchase Program, from the Company&amp;#8217;s Chief Executive Officer&#13;at $1.00 per share. These shares were repurchased at a discount to market to provide for an orderly disposition of the shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 id="f311" decimals="INF" contextRef="c83" unitRef="pure">0.101</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f312" decimals="0" contextRef="c84" unitRef="usd">2341.0</us-gaap:StockholdersEquity>
  <us-gaap:CostOfRevenue id="f313" decimals="0" contextRef="c5" unitRef="usd">6806142.0</us-gaap:CostOfRevenue>
  <us-gaap:AssetsCurrent id="f314" decimals="0" contextRef="c1" unitRef="usd">27141700.0</us-gaap:AssetsCurrent>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="f315" decimals="0" contextRef="c3" unitRef="usd">563277.0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="f316" contextRef="c5">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Three months&amp;#160;ended April 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Six months&amp;#160;ended April 30,&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%"&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Net income available to common equity holders - used to compute&amp;#160;basic and diluted earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$687,561&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$707,483&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$1,214,461&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;$1,178,503&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of common shares - used to compute basic earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,001,627&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,002,903&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,002,745&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,032,107&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Effect of options to purchase common stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;27,576&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;66,020&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,213&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;73,059&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Weighted average number of shares - used to compute diluted earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,029,203&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,068,923&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,025,958&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;&amp;#160;23,105,166&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentNet id="f317" decimals="0" contextRef="c14" unitRef="usd">290658.0</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:SharesIssued id="f318" decimals="INF" contextRef="c50" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f319" decimals="INF" contextRef="c10" unitRef="shares">340000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ConcentrationRiskPercentage1 id="f320" decimals="INF" contextRef="c85" unitRef="pure">0.715</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f321" decimals="0" contextRef="c86" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:CostOfRevenue id="f322" decimals="0" contextRef="c3" unitRef="usd">3556942.0</us-gaap:CostOfRevenue>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f323" decimals="0" contextRef="c10" unitRef="usd">0.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:SharesIssued id="f324" decimals="INF" contextRef="c82" unitRef="shares">23397707.0</us-gaap:SharesIssued>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="f325" decimals="0" contextRef="c14" unitRef="usd">509275.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f326" decimals="0" contextRef="c87" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="f327" decimals="INF" contextRef="c84" unitRef="shares">23405753.0</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f328" decimals="0" contextRef="c10" unitRef="usd">12000.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <pharmabioserv.com:RecentAccountingPronouncementsPolicyTextBlock id="f329" contextRef="c5">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Recent accounting pronouncements pending adoption&#13;not discussed above or in the 2019 Form 10-K are either not applicable or will not have or are not expected to have a material&#13;impact on us.&lt;/p&gt;</pharmabioserv.com:RecentAccountingPronouncementsPolicyTextBlock>
  <us-gaap:PrepaidExpenseAndOtherAssets id="f330" decimals="0" contextRef="c1" unitRef="usd">332722.0</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:GrossProfit id="f331" decimals="0" contextRef="c4" unitRef="usd">3072462.0</us-gaap:GrossProfit>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f332" decimals="INF" contextRef="c4" unitRef="shares">73059.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:ConcentrationRiskPercentage1 id="f333" decimals="INF" contextRef="c88" unitRef="pure">0.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SharesIssued id="f334" decimals="INF" contextRef="c86" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f335" decimals="0" contextRef="c4" unitRef="usd">500000.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:StockholdersEquity id="f336" decimals="0" contextRef="c89" unitRef="usd">1364956.0</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit id="f337" decimals="0" contextRef="c5" unitRef="usd">3454792.0</us-gaap:GrossProfit>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f338" decimals="INF" contextRef="c5" unitRef="shares">23213.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:SharesIssued id="f339" decimals="INF" contextRef="c87" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f340" decimals="0" contextRef="c5" unitRef="usd">0.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:ConcentrationRiskPercentage1 id="f341" decimals="INF" contextRef="c90" unitRef="pure">0.107</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f342" decimals="0" contextRef="c91" unitRef="usd">1403936.0</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit id="f343" decimals="0" contextRef="c3" unitRef="usd">1593402.0</us-gaap:GrossProfit>
  <us-gaap:SharesIssued id="f344" decimals="INF" contextRef="c92" unitRef="shares">23377259.0</us-gaap:SharesIssued>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="f345" decimals="INF" contextRef="c3" unitRef="shares">66020.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <us-gaap:AssetsCurrent id="f346" decimals="0" contextRef="c14" unitRef="usd">25974980.0</us-gaap:AssetsCurrent>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f347" decimals="0" contextRef="c10" unitRef="usd">1148516.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromCollectionOfOtherReceivables id="f348" decimals="0" contextRef="c3" unitRef="usd">500000.0</us-gaap:ProceedsFromCollectionOfOtherReceivables>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f349" decimals="0" contextRef="c4" unitRef="usd">2163033.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SharesIssued id="f350" decimals="INF" contextRef="c93" unitRef="shares">0.0</us-gaap:SharesIssued>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f351" decimals="INF" contextRef="c10" unitRef="shares">0.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <us-gaap:AccountsReceivableNetCurrent id="f352" decimals="0" contextRef="c14" unitRef="usd">8781026.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:ConcentrationRiskPercentage1 id="f353" decimals="INF" contextRef="c94" unitRef="pure">0.105</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f354" decimals="0" contextRef="c95" unitRef="usd">20289611.0</us-gaap:StockholdersEquity>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f355" decimals="0" contextRef="c10" unitRef="usd">27548.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <pharmabioserv.com:PromissoryNoteReceivableCurrent id="f356" decimals="0" contextRef="c1" unitRef="usd">1250000.0</pharmabioserv.com:PromissoryNoteReceivableCurrent>
  <us-gaap:SharesIssued id="f357" decimals="INF" contextRef="c96" unitRef="shares">23405753.0</us-gaap:SharesIssued>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f358" decimals="INF" contextRef="c4" unitRef="shares">80000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f359" decimals="0" contextRef="c5" unitRef="usd">2197649.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f360" decimals="0" contextRef="c4" unitRef="usd">99038.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f361" decimals="0" contextRef="c97" unitRef="usd">20687529.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="f362" decimals="INF" contextRef="c98" unitRef="shares">0.0</us-gaap:SharesIssued>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f363" decimals="INF" contextRef="c5" unitRef="shares">340000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock id="f364" contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Three months ended April 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;b&gt;Six months ended April 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;REVENUES:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; text-indent: 9pt"&gt;Puerto Rico consulting&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;5,116,682&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;4,293,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;9,297,592&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 5%; text-align: right"&gt;8,181,595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;United States consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;394,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;784,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,188,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Europe consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;233,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Other segments&amp;#185;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total consolidated revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,647,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,150,344&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,260,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,716,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;INCOME (LOSS) BEFORE TAXES:&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 12pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Puerto Rico consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;633,633&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;581,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,150,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;956,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;United States consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: right"&gt;(61,930&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Europe consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,014&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,684&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,925&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 9pt"&gt;Other segments&amp;#185;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,733&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;195,506&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;324,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 0.25in"&gt;Total consolidated income before taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;768,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;782,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,351,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,296,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 id="f365" decimals="INF" contextRef="c99" unitRef="pure">0.116</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f366" decimals="0" contextRef="c5" unitRef="usd">12000.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ShareBasedCompensation id="f367" decimals="0" contextRef="c10" unitRef="usd">11430.0</us-gaap:ShareBasedCompensation>
  <us-gaap:PrepaidExpenseAndOtherAssets id="f368" decimals="0" contextRef="c14" unitRef="usd">453780.0</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:StockholdersEquity id="f369" decimals="0" contextRef="c100" unitRef="usd">92522.0</us-gaap:StockholdersEquity>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="f370" decimals="0" contextRef="c3" unitRef="usd">1116474.0</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="f371" decimals="INF" contextRef="c3" unitRef="shares">80000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="f372" decimals="0" contextRef="c3" unitRef="usd">99038.0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ConcentrationRiskPercentage1 id="f373" decimals="INF" contextRef="c101" unitRef="pure">0.222</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f374" decimals="0" contextRef="c102" unitRef="usd">102133.0</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensation id="f375" decimals="0" contextRef="c5" unitRef="usd">22860.0</us-gaap:ShareBasedCompensation>
  <us-gaap:NonoperatingIncomeExpense id="f376" decimals="0" contextRef="c10" unitRef="usd">48584.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f377" decimals="0" contextRef="c1" unitRef="usd">15581997.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f378" decimals="0" contextRef="c4" unitRef="usd">38844.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ConcentrationRiskPercentage1 id="f379" decimals="INF" contextRef="c103" unitRef="pure">0.249</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccountsReceivableNetCurrent id="f380" decimals="0" contextRef="c1" unitRef="usd">9976981.0</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:ConcentrationRiskPercentage1 id="f381" decimals="INF" contextRef="c104" unitRef="pure">0.55</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:StockholdersEquity id="f382" decimals="0" contextRef="c105" unitRef="usd">-392007.0</us-gaap:StockholdersEquity>
  <us-gaap:NonoperatingIncomeExpense id="f383" decimals="0" contextRef="c5" unitRef="usd">94020.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ShareBasedCompensation id="f384" decimals="0" contextRef="c106" unitRef="usd">11430.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram id="f385" decimals="INF" contextRef="c1" unitRef="shares">341154.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f386" decimals="INF" contextRef="c41" unitRef="pure">0.852</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f387" decimals="0" contextRef="c5" unitRef="usd">38874.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:StockholdersEquity id="f388" decimals="0" contextRef="c107" unitRef="usd">-394278.0</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensation id="f389" decimals="0" contextRef="c3" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:PromissoryNoteReceivableCurrent id="f390" decimals="0" contextRef="c14" unitRef="usd">1250000.0</pharmabioserv.com:PromissoryNoteReceivableCurrent>
  <us-gaap:NonoperatingIncomeExpense id="f391" decimals="0" contextRef="c3" unitRef="usd">305813.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ShareBasedCompensation id="f392" decimals="0" contextRef="c4" unitRef="usd">18000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="f393" decimals="0" contextRef="c3" unitRef="usd">35761.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f394" decimals="INF" contextRef="c4" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f395" decimals="0" contextRef="c10" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:StockholdersEquity id="f396" decimals="0" contextRef="c92" unitRef="usd">2338.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f397" decimals="INF" contextRef="c5" unitRef="shares">0.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <us-gaap:ShareBasedCompensation id="f398" decimals="0" contextRef="c108" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f399" decimals="0" contextRef="c10" unitRef="usd">1928961.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare id="f400" decimals="INF" contextRef="c3" unitRef="shares">1000000.0</pharmabioserv.com:AntidilutiveWarrantsExcludedFromComputationOfEarningsPerShare>
  <us-gaap:OperatingIncomeLoss id="f401" decimals="0" contextRef="c4" unitRef="usd">909429.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:StockholdersEquity id="f402" decimals="0" contextRef="c93" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f403" decimals="INF" contextRef="c109" unitRef="pure">0.093</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NonoperatingIncomeExpense id="f404" decimals="0" contextRef="c4" unitRef="usd">387287.0</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ShareBasedCompensation id="f405" decimals="0" contextRef="c11" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f406" decimals="0" contextRef="c4" unitRef="usd">-44475.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f407" decimals="0" contextRef="c10" unitRef="usd">768968.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:StockholdersEquity id="f408" decimals="0" contextRef="c110" unitRef="usd">1355956.0</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f409" decimals="0" contextRef="c42" unitRef="usd">16029920.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="f410" decimals="0" contextRef="c10" unitRef="usd">687561.0</pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <us-gaap:ShareBasedCompensation id="f411" decimals="0" contextRef="c111" unitRef="usd">9000.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f412" decimals="0" contextRef="c5" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:StockholdersEquity id="f413" decimals="0" contextRef="c112" unitRef="usd">19582131.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f414" decimals="0" contextRef="c43" unitRef="usd">581019.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f415" decimals="0" contextRef="c14" unitRef="usd">15490174.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable id="f416" decimals="INF" contextRef="c85" unitRef="pure">0.861</pharmabioserv.com:AmountDueFromMajorCustomersAsPercentageOfAccountsReceivable>
  <us-gaap:ShareBasedCompensation id="f417" decimals="0" contextRef="c113" unitRef="usd">11430.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue id="f418" decimals="0" contextRef="c1" unitRef="usd">331306.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f419" decimals="0" contextRef="c45" unitRef="usd">633633.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram id="f420" decimals="INF" contextRef="c14" unitRef="shares">338854.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgram>
  <us-gaap:OperatingIncomeLoss id="f421" decimals="0" contextRef="c10" unitRef="usd">720384.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:StockholdersEquity id="f422" decimals="0" contextRef="c114" unitRef="usd">115789.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:DisposalOfMarketableSecurities id="f423" decimals="0" contextRef="c3" unitRef="usd">0.0</pharmabioserv.com:DisposalOfMarketableSecurities>
  <us-gaap:ShareBasedCompensation id="f424" decimals="0" contextRef="c18" unitRef="usd">11430.0</us-gaap:ShareBasedCompensation>
  <pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="f425" decimals="0" contextRef="c4" unitRef="usd">1178503.0</pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <us-gaap:StockholdersEquity id="f426" decimals="0" contextRef="c115" unitRef="usd">-370443.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f427" decimals="0" contextRef="c3" unitRef="usd">782741.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f428" decimals="0" contextRef="c4" unitRef="usd">-149709.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f429" decimals="0" contextRef="c22" unitRef="usd">15433111.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="f430" decimals="0" contextRef="c5" unitRef="usd">1214461.0</pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless id="f431" decimals="INF" contextRef="c116" unitRef="shares">3442.0</pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless>
  <pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue id="f432" decimals="0" contextRef="c14" unitRef="usd">329607.0</pharmabioserv.com:SharesPurchasedUnderRepurchaseProgramValue>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f433" decimals="0" contextRef="c37" unitRef="usd">-41887.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f434" decimals="0" contextRef="c5" unitRef="usd">199265.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted id="f435" decimals="0" contextRef="c3" unitRef="usd">707483.0</pharmabioserv.com:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f436" decimals="0" contextRef="c3" unitRef="usd">58993.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:StockholdersEquity id="f437" decimals="0" contextRef="c117" unitRef="usd">20685771.0</us-gaap:StockholdersEquity>
  <us-gaap:ConcentrationRiskPercentage1 id="f438" decimals="INF" contextRef="c118" unitRef="pure">0.0</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f439" decimals="0" contextRef="c117" unitRef="usd">15798526.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OperatingIncomeLoss id="f440" decimals="0" contextRef="c5" unitRef="usd">1257143.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f441" decimals="0" contextRef="c49" unitRef="usd">14230.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f442" decimals="0" contextRef="c119" unitRef="usd">1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:StockholdersEquity id="f443" decimals="0" contextRef="c96" unitRef="usd">2341.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f444" decimals="0" contextRef="c53" unitRef="usd">7489.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="f445" decimals="0" contextRef="c3" unitRef="usd">-80557.0</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ConcentrationRiskPercentage1 id="f446" decimals="INF" contextRef="c120" unitRef="pure">0.111</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f447" decimals="0" contextRef="c44" unitRef="usd">15254752.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OperatingIncomeLoss id="f448" decimals="0" contextRef="c3" unitRef="usd">476928.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:LiabilitiesCurrent id="f449" decimals="0" contextRef="c1" unitRef="usd">2711747.0</us-gaap:LiabilitiesCurrent>
  <us-gaap:ProceedsFromLoans id="f450" decimals="0" contextRef="c10" unitRef="usd">1931700.0</us-gaap:ProceedsFromLoans>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f451" decimals="0" contextRef="c56" unitRef="usd">-8014.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f452" decimals="0" contextRef="c28" unitRef="usd">-1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:PaymentsOfDividends id="f453" decimals="0" contextRef="c10" unitRef="usd">0.0</us-gaap:PaymentsOfDividends>
  <us-gaap:StockholdersEquity id="f454" decimals="0" contextRef="c98" unitRef="usd">0.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f455" decimals="0" contextRef="c58" unitRef="usd">169733.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f456" decimals="0" contextRef="c18" unitRef="usd">0.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:ConcentrationRiskPercentage1 id="f457" decimals="INF" contextRef="c121" unitRef="pure">0.146</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccruedIncomeTaxesCurrent id="f458" decimals="0" contextRef="c1" unitRef="usd">476881.0</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:ProceedsFromLoans id="f459" decimals="0" contextRef="c4" unitRef="usd">0.0</us-gaap:ProceedsFromLoans>
  <us-gaap:StockholdersEquity id="f460" decimals="0" contextRef="c122" unitRef="usd">1392506.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f461" decimals="0" contextRef="c61" unitRef="usd">195506.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f462" decimals="0" contextRef="c3" unitRef="usd">-1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:PaymentsOfDividends id="f463" decimals="0" contextRef="c4" unitRef="usd">0.0</us-gaap:PaymentsOfDividends>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f464" decimals="0" contextRef="c5" unitRef="usd">1351163.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless id="f465" decimals="INF" contextRef="c119" unitRef="shares">8046.0</pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless>
  <us-gaap:ConcentrationRiskPercentage1 id="f466" decimals="INF" contextRef="c123" unitRef="pure">0.099</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ProceedsFromLoans id="f467" decimals="0" contextRef="c5" unitRef="usd">1931700.0</us-gaap:ProceedsFromLoans>
  <us-gaap:StockholdersEquity id="f468" decimals="0" contextRef="c124" unitRef="usd">19999968.0</us-gaap:StockholdersEquity>
  <us-gaap:PaymentsOfDividends id="f469" decimals="0" contextRef="c5" unitRef="usd">1725295.0</us-gaap:PaymentsOfDividends>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f470" decimals="0" contextRef="c4" unitRef="usd">1296716.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:LiabilitiesCurrent id="f471" decimals="0" contextRef="c14" unitRef="usd">3670540.0</us-gaap:LiabilitiesCurrent>
  <pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless id="f472" decimals="INF" contextRef="c125" unitRef="shares">20448.0</pharmabioserv.com:StockIssuedDuringPeriodSharesStockOptionsExercisedCashless>
  <us-gaap:StockholdersEquity id="f473" decimals="0" contextRef="c126" unitRef="usd">131866.0</us-gaap:StockholdersEquity>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f474" decimals="0" contextRef="c67" unitRef="usd">1150772.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:PaymentsOfDividends id="f475" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:PaymentsOfDividends>
  <us-gaap:ConcentrationRiskPercentage1 id="f476" decimals="INF" contextRef="c127" unitRef="pure">0.682</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:DividendsPayableCurrent id="f477" decimals="0" contextRef="c14" unitRef="usd">1725295.0</us-gaap:DividendsPayableCurrent>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f478" decimals="0" contextRef="c26" unitRef="usd">-3.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f479" decimals="0" contextRef="c10" unitRef="usd">2739.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ProceedsFromLoans id="f480" decimals="0" contextRef="c3" unitRef="usd">0.0</us-gaap:ProceedsFromLoans>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f481" decimals="0" contextRef="c70" unitRef="usd">-61930.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <dei:EntityRegistrantName id="f482" contextRef="c5">Pharma-Bio Serv, Inc.</dei:EntityRegistrantName>
  <us-gaap:StockholdersEquity id="f483" decimals="0" contextRef="c128" unitRef="usd">-394278.0</us-gaap:StockholdersEquity>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f484" decimals="0" contextRef="c125" unitRef="usd">2.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:DividendsPayableCurrent id="f485" decimals="0" contextRef="c1" unitRef="usd">0.0</us-gaap:DividendsPayableCurrent>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f486" decimals="0" contextRef="c71" unitRef="usd">-61684.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="f487" decimals="0" contextRef="c5" unitRef="usd">5441.0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ConcentrationRiskPercentage1 id="f488" decimals="INF" contextRef="c129" unitRef="pure">0.598</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AccruedIncomeTaxesCurrent id="f489" decimals="0" contextRef="c14" unitRef="usd">344043.0</us-gaap:AccruedIncomeTaxesCurrent>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f490" decimals="0" contextRef="c11" unitRef="usd">1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
  <us-gaap:ConcentrationRiskPercentage1 id="f491" decimals="INF" contextRef="c130" unitRef="pure">0.118</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="f492" decimals="0" contextRef="c74" unitRef="usd">324005.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless id="f493" decimals="0" contextRef="c116" unitRef="usd">1.0</pharmabioserv.com:StockIssuedDuringPeriodValueStockOptionsExercisedCashless>
</xbrli:xbrl>
